Development and validation of pyroptosis-related lncRNAs prediction model for bladder cancer. Issue 1 (28th January 2022)

• Record Type: Journal Article
• Authors: Lia, Thongher; Shao, Yanxiang; Regmi, Parbatraj; Li, Xiang
• Is Part Of: Bioscience reports. Volume 42:Issue 1(2022)
• Publication Date: 2022-01-28
• Subjects: bladder cancer -- long non-coding RNA -- prognostic biomarker -- pyroptosis; Molecular biology -- Periodicals; Cytology -- Periodicals; 572.8
• DOI: 10.1042/BSR20212253
• Languages: English
• ISSNs: 0144-8463

Abstract

Abstract: Bladder cancer (BLCA) is one of the highly heterogeneous disorders accompanied by a poor prognosis. The present study aimed to construct a model based on pyroptosis-related long-stranded non-coding RNA (lncRNA) to evaluate the potential prognostic application in bladder cancer. The mRNA expression profiles of bladder cancer patients and corresponding clinical data were downloaded from the public database from The Cancer Genome Atlas (TCGA). Pyroptosis-related lncRNAs were identified by utilizing a co-expression network of pyroptosis-related genes and lncRNAs. The lncRNA was further screened by univariate Cox regression analysis. Finally, eight pyroptosis-related lncRNA markers were established using least absolute shrinkage and selection operator (Lasso) regression and multivariate Cox regression analyses. Patients were separated into high- and low-risk groups based on the performance value of the median risk score. Patients in the high-risk group had significantly poorer overall survival (OS) than those in the low-risk group ( P <0.001). In multivariate Cox regression analysis, the risk score was an independent predictive factor of OS (HR > 1, P <0.01). The areas under the curve (AUCs) of the 3- and 5-year OS in the receiver operating characteristic (ROC) curve were 0.742 and 0.739, respectively. In conclusion, these eight pyroptosis-related lncRNA and their markers may be potential molecular markers and therapeutic targets for bladder cancer patients.